Anika Q3 revenue $40.3M (+2% YoY); net loss ($4.2M); Cingal Phase III hits endpoint

Anika Therapeutics, Inc.

2022-Q3 EPS reported -$0.68 revenue$116,614,000

Revenue $40.3M (+2% YoY); OA Pain Mgmt $25.7M (-2%), Joint Preservation $11.8M (+6%), Non-Ortho $2.8M (+27%).
Net loss ($4.2M) vs net income $0.6M prior year; adjusted net loss ($0.7M); adjusted EBITDA $4.1M vs $5.7M.
Cingal Phase III (Cingal 19-01) achieved primary endpoint — superiority over steroid alone at 26 weeks; FDA meeting planned.
Hyalofast pivotal Phase III 96% enrolled (193 patients); full enrollment expected early 2023; PMA filing on track for 2025.
FY2022 guidance: overall revenue toward upper end of low to mid single-digit growth; OA Pain Mgmt now expected up mid to upper single-digit %.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anika Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $40.3 million, net income ($4.2) million, or ($0.29) per share, EPS ($0.29) per share.

Period: third quarter ended September 30, 2022
Revenue: $40.3 million
Net income: ($4.2) million, or ($0.29) per share
EPS: ($0.29) per share
Result: reported results

Exact text from the filing

orthopedics, today reported financial results for its third quarter ended September 30, 2022. Third Quarter 2022 Financial Summary Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021. OA Pain Management 1 revenue of $25.7 million, down 2% Joint Preservation and Restoration revenue of $11.8

View on SEC.gov

Browse all earnings releases →

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.